<div id="readability-page-1"><h3>President's Day Sale - 70% Off</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Satellos Bioscience ( (TSE:MSCL) ) has provided an announcement. On February 18, 2026, Satellos Bioscience Inc. announced it will host a virtual key opinion leader event on February 24, 2026, featuring neuromuscular expert Dr. Kevin M. Flanigan to discuss the unmet need and current treatment landscape in Duchenne muscular dystrophy. The event will highlight clinical progress for SAT-3247, including Phase 1a/b data in healthy volunteers and adults with DMD, the TRAILHEAD open-label adult study, and the BASECAMP randomized Phase 2 pediatric trial, underscoring Satellos’ efforts to position SAT-3247 as a potentially disease-modifying, dystrophin-independent therapy in a competitive DMD market. The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page. Spark’s Take on TSE:MSCL Stock According to Spark, TipRanks’ AI Analyst, TSE:MSCL is a Neutral. The score is held down primarily by weak financial performance (pre-revenue, large losses, and heavy cash burn with ongoing funding risk). Technicals are supportive due to a clear uptrend, but overbought signals temper that strength. Valuation is also constrained by negative earnings and no dividend support. To see Spark’s full report on TSE:MSCL stock, click here. More about Satellos Bioscience Satellos Bioscience Inc. is a clinical-stage biotechnology company developing orally administered small molecule medicines to restore natural muscle repair and regeneration in degenerative muscle diseases. Its lead candidate, SAT-3247, targets the AAK1 protein to address disrupted muscle stem-cell signaling in Duchenne muscular dystrophy (DMD) and is being evaluated in ongoing Phase 2 clinical trials in adult and pediatric patients. Average Trading Volume: 32,482 Technical Sentiment Signal: Buy Current Market Cap: C$243.3M See more data about MSCL stock on TipRanks’ Stock Analysis page.</div>

TBIO

MSLE

SBIO

Satellos Bioscience Inc. will host a virtual KOL event on February 24, 2026, featuring Dr. Kevin M. Flanigan to discuss Duchenne muscular dystrophy and the clinical progress of SAT-3247. The event will cover Phase 1a/b data and ongoing trials, positioning SAT-3247 as a potential therapy in the DMD market. Analyst ratings for TSE:MSCL stock indicate a Buy with a C$16.00 price target, though concerns about financial performance and cash burn persist. Satellos focuses on developing treatments for degenerative muscle diseases, with SAT-3247 targeting AAK1 protein in DMD patients.

Tip Ranks

Telesis Bio

SPDR S&P Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Satellos Bioscience

ALPS Medical Breakthrough

VanEck Biotech ETF

Satellos to Host February 24 Virtual KOL Event Showcasing SAT-3247 in Duchenne Muscular Dystrophy